Pharmacogenomic tests for insurers
Reduce disability-related costs through pharmacogenomics and improve the health and well-being of your policyholders
Pharmacogenomic (PGx) tests can help healthcare professionals make better medication choices to accelerate recovery, prevent absenteeism and reduce disability benefits payable to policyholders.
What is a pharmacogenomic or PGx testing?
Pharmacogenomic testing (PGx) is now a key tool for insurance companies. Its aim is to establish the compatibility of a drug with a patient’s metabolism, based on a DNA test. With PGx testing, healthcare professionals can determine whether a drug has an increased risk of being ineffective or causing significant side effects in a particular patient. Thus, these tests reduce trial-and-error periods by helping healthcare professionals find the right treatment for a patient’s specific needs faster, based on their genetic profile.
Mental health—a major issue with disability and presenteeism
The benefits of pharmacogenomic testing for insurers
Reducing claims and shortening disability periods
Faster treatment
Reducing the costs of ineffective medications
Improving the well-being of policyholders
When should insurers use pharmacogenomic testing?
- In group insurance plans
- When managing disability claims
- When absenteeism or presenteeism is an issue
The benefits of pharmacogenomic testing are measurable
Sources: Internal data and [5].
The benefits of the Biron pharmacogenomic (PGx) tests
Support for plan managers
A dedicated portal for your policyholders
Report covering 145 medications used to treat mental health and pain problems
Rapid results within 10 days
Data security and confidentiality
Accreditations and certifications
Alongside these advantages, Biron Genetics holds a number of accreditations and certifications that testify to our commitment to data security and clinical excellence.
Our laboratory is CAP certified – College of American Pathologists
Our systems are Soc2 Type II accredited
Pharmacogenomic tests for insurers
Complete pharmacogenomic test
High clinical relevance
The panel of genes tested with the Biron Mental Health test is the most extensive and the most relevant for psychiatry and ADHD, compared with other tests currently available in Canada.
Want to learn more about how pharmacogenomics can help you?
Our team of experts is available
FAQ
Do insurers have access to the results of the reports?
No. Client results are never shared with a third party without their consent. If you wish to access them, the patient’s consent must first be obtained.
How is the data secured?
Genetic data is encrypted on multiple levels and stored on Canadian servers that meet the highest security standards. Our SOC2 Type 2 certification is tested annually by an external auditor to ensure the robustness of our systems. Biron Genetics protects access to genetic data by letting each patient control who can access their information.
For how long are the results valid?
Since the genetic code does not change, the results will be the same whether the test is taken at the age of 7 or 70. However, science evolves, and it is possible that the interpretation of the results will change over time. The report will be updated periodically at no additional charge to ensure that the client and their healthcare professional have the most current and scientifically sound information possible. Additional charges may apply if further genetic testing is required.
Sources5
- https://www.benefitscanada.com/benefits/health-benefits/more-than-a-third-of-disability-claims-in-2022-due-to-mental-health-reasons-survey/
- Cascade et al. (2009) Psychiatry (Edgmont) 6(2):16-18.
- Trivedi et al. (2006) Am J Psych 163, 28-40.
- [Cascade et al. Psychiatry (2009) 163, 28-40]
- Brown et al. (2022) Clin Pharmacol Ther 112(6):1303-1317.